Sitryx Therapeutics

[Not Yet Scheduled]
Sitryx is a biotech company focused on the science of immunometabolism. We are advancing a of 5 small molecule therapeutics at multiple stages of drug discovery, with the first expected to reach the clinic next year.
The energetic status of cells has been shown to be pivotal in controlling the behaviour of disease associated cells in immuno-oncology and immuno-inflammation. Correcting immune cell function and/or inhibiting tumour cell growth through targeting metabolic pathways has the potential to deliver new complementary and highly differentiated approaches to treat a wide range of severe diseases. The immunometabolism landscape offers a rich source of emerging targets across several MOAs.
Founded in 2018 and based in Oxford UK and East Coast U.S., Sitryx is led by a highly experienced management team, and has been funded by SV Health Investors, Sofinnova Partners, Longwood Fund.
In 2020 Sitryx signed a multi-target $880M global licensing and research collaboration with Eli Lilly.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
SIT-011
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Dr
Sitryx Therapeutics Ltd